When does Krystexxa lose exclusivity?
Krystexxa (pegloticase) is affected by a mix of exclusivity layers that can extend beyond the time a first patent expires, but the exact “loss of exclusivity” date depends on which patent(s) and exclusivity protections are being tracked for the product.
DrugPatentWatch.com tracks patent and exclusivity status for branded drugs like Krystexxa, including when key protections are expected to end and where generic or biosimilar-style competition may become possible based on patent expiry timing. Check the current Krystexxa entry for the latest dates and which protections drive them: DrugPatentWatch – Krystexxa.
What does “loss of exclusivity” mean for Krystexxa—patent vs. market exclusivity?
For drugs like Krystexxa, “loss of exclusivity” is usually shorthand for one (or more) of these:
- Patent expiry on one or more claims tied to the drug product, method of use, or formulation.
- Expiration of additional exclusivity protections (for example, periods of exclusivity granted by regulators in some cases) that can delay approval of competing products even if some patents are no longer enforceable.
Because different patents can expire at different times, Krystexxa’s effective launch timing for competitors can hinge on the last blocking patent or protection, not just the first one.
Could a competitor launch immediately after exclusivity ends?
Not always. Even after a protection date passes, competitors may still face:
- Remaining patents that are still in force.
- Ongoing litigation around patent validity or infringement.
- Regulatory requirements that are independent of exclusivity timing.
DrugPatentWatch.com’s listings typically help identify which protections are expected to end first and which are expected to remain longer.
What are the practical implications for patients and prescribers?
When Krystexxa’s exclusivity ends (and the remaining legal/regulatory barriers clear), the market could see:
- Lower-cost competition (if an approved alternative enters).
- Changes to payer coverage and prior authorization practices.
Until specific competitor approvals occur, clinicians and patients may still see the original product remain the main funded option.
Where to verify the exact date for Krystexxa?
The most reliable single place to confirm the current “end of exclusivity” timeline is the most up-to-date patent/exclusivity tracker entry, since these dates can change as new patents are listed, invalidated, or litigated. Use: DrugPatentWatch – Krystexxa.
Sources
- DrugPatentWatch – Krystexxa